ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Nodal status in predicting the outcome of treatment with definitive chemoradiation in patients with cervical cancer in FIGO IIIC1 and IIIC2 stages.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The 2018 International Federation of Gynecology and Obstetrics (FIGO) classification redefined stage III of locally advanced cervical cancer into substages IIIC1 pelvic and IIIC2 para-aortic lymphadenopathy, ignoring the number and size of lymph nodes. The aim was to analyse of the volume burden influence of the primary tumor and pathological lymph nodes, on the three-year overall survival (OS) and progression free survival (PFS), in cervical cancer patients FIGO stages IIIC1 and IIIC2 treated with definitive chemoradiation. Materials and methods: A retrospective clinical study based on the analysis of three-year OS, PFS and factors that may influence the time to disease progression in cervical cancer patients in FIGO IIIC1 and IIIC2 stages treated from January 2020 to January 2024 with external beam radiotherapy (EBRT) with simultaneous integrated or sequential boost doses, brachytherapy and chemopotentiation at the Radiation Oncology Center of the UCC Kragujevac. Results: The study included 92 patients whose three-year OS was 68.5%, while PFS was 57.6%. The influence of age, comorbidity, belonging to stage IIIC1 or IIIC2, pathohistological tumor characteristics, number, total volume (GTVn) or the presence of a conglomerate of lymph nodes, tumor volume (GTVt), treatment duration over 56 days and radiotherapy technique on the length of PFS was examined. The length of PFS is influenced by treatment duration over 56 days, GTVn, number and conglomeration of lymph nodes, and EBRT dose (p < 0.05). Conclusions: The number and total volume of lymph nodes have a statistically significant effect on the length of PFS in FIGO stage IIIC1 and IIIC2 cervical cancer patients treated with definitive chemoradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.